Home › Therapeutic areas › Agents for purulent diseases
Japan market screening · Therapeutic class
化膿性疾患用剤 · Japan Standard Commodity Classification
10 molecules in this class are marketed in Japan across 47 products. 18 of those products are not shipping normally today — 38.3% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.
Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.
| Molecule | Products | Companies | Constrained | Supply mix |
|---|---|---|---|---|
| Clindamycin Phosphateクリンダマイシンリン酸エステル | 18 | 10 | 6 | |
| Chloramphenicolクロラムフェニコール | 8 | 3 | 7 | |
| Nadifloxacinナジフロキサシン | 7 | 3 | 2 | |
| Tetracycline Hydrochlorideテトラサイクリン塩酸塩 | 5 | 1 | 3 | |
| Fradiomycin Sulfateフラジオマイシン硫酸塩 | 3 | 2 | — | |
| Ozenoxacinオゼノキサシン | 2 | 1 | — | |
| Bacitracin / Fradiomycin Sulfateバシトラシン・フラジオマイシン硫酸塩 | 1 | 1 | — | |
| Oxytetracycline Hydrochloride / Polymixin B Sulfateオキシテトラサイクリン塩酸塩・ポリミキシンＢ硫酸塩 | 1 | 1 | — | |
| Sodium Fusidateフシジン酸ナトリウム | 1 | 1 | — | |
| Sulfadiazine Silverスルファジアジン銀 | 1 | 1 | — |
Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.
Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).